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Infectious Agents and Cancer is introducing a new section on Cancer Centers in Low- and Middle-Income Countries
intended to provide the oncology community with detailed information about lessons learned in cancer control in
resource-limited settings. The growing burden of cancer and the high rates of infection-related cancers in Low- and
Middle-Income Countries (LMICs) argue for exploring the successes and challenges of cancer centers in low-resource
settings. Detailed analyses are needed on how successful cancer centers have developed and managed such key
components as strategic partnerships, trained cancer professionals, sustainable funding, appropriate technology,
and research capacity. Many examples exist wherein local cancer centers have made significant progress and as such,
the series will provide a platform to showcase detailed features of cancer institutes in LMICs and provide valuable
information for those seeking to replicate successful models and to help invigorate efforts to build cancer capacity.Infectious Agents and Cancer is pleased to present a
section entitled Cancer Centers in Low- and Middle-
Income Countries. As low- and middle- income coun-
tries (LMICs) continue to face health challenges from
infectious disease, they are concurrently challenged by
the rising burden of non-communicable diseases in-
cluding cancer. The International Agency for Research
on Cancer (IARC) projects that by 2030, the annual
number of new cancer cases worldwide will exceed 21
million and the number of cancer deaths will reach 13
million [1]. The World Health Organization (WHO) esti-
mates that about 70% of all cancer deaths occur in LMICs
and more than 20% of cancers in LMICs are directly
attributable to infectious agents [2]. Infectious agents
associated with cancers more frequently found in de-
veloping countries include Epstein-Barr virus (EBV),
Kaposi sarcoma-associated herpesvirus/human herpes-
virus 8 (KSHV/HHV8), human papillomavirus (HPV),
hepatitis B and C viruses (HBV/HCV), human T-
lymphotropic virus type 1 (HTLV-1), the bacterium
Helicobacter pylori, and parasites Opisthorchis viverrini
and Schistosoma haematobium. In Sub-Saharan Africa,
the fraction of infection-related cancers is particularly high
at 32.7% [3]. These numbers provide a compelling reason* Correspondence: bhatiak@mail.nih.gov
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article, unless otherwise stated.to explore successful strategies for enhancing cancer pre-
vention and control capacity in LMICs. This enhanced
capacity in LMICs includes strategic partnerships, well-
trained professionals, appropriate technology, strengthened
health systems, sustainable funding, and a solid research
base to strengthen development of locally appropriate so-
lutions in the fight against cancer.
Existing models of collaborative partnerships between
a combination of low-, middle- and upper-income coun-
try cancer centers could provide useful pointers for
improving cancer prevention and control capacity in low-
resource settings. The challenges posed by the rising
burden of cancer in Africa for instance, has already begun
to influence new partnerships and expand previously
existing partnerships between institutions globally. For
instance, the long-term “twinning” program between
Indiana University and Moi University in Kenya, AMPATH
(Academic Model Providing Access to Healthcare), has
built a strong foundation for health-related research and
has put in place detailed standard operating procedures to
ensure the continued success of the partnership [4].
Amongst the AMPATH program’s recent successes in
Kenya in the field of cancer are training and mentoring
of local oncology researchers [5] and nurses [6], cre-
ating oncology pharmacies [7], and evaluating chemo-
therapy outcomes for AIDS-associated Kaposi sarcoma
[8]. Other examples of successful collaboration between
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Medical Research Institute (KEMRI) and the Uganda
Cancer Institute (UCI)/Hutchinson Cancer Center Alliance.
The UNC/KEMRI collaboration has recently investi-
gated HPV testing with self-collection of samples [9]
and women’s attitudes toward HPV vaccine in Kenya
[10]. The UCI/Hutchinson Cancer Center Alliance re-
searchers have established that HIV plays a role in decreas-
ing cancer survival in Uganda [11] and have investigated
how gender influences Kaposi sarcoma presentation
and outcomes [12]. Such collaborative partnerships
can help catalyze a local institution’s capacity to provide
preventive services, implement screening programs, de-
liver treatment and palliative care, procure quality cancer
drugs, train allied health professionals in cancer care,
strengthen cancer research on locally significant problems,
support best practices in cancer care and research, de-
velop healthcare informatics, and much more.
In addition to partnerships between institutions in
high- and low-income countries, there is also a clear
need to understand how institutes in LMICs can support
one another in cancer prevention, control and research.
With the increased strength of biological sciences in
many developing countries [13], significant progress is
certainly within reach and extending the benefits to cancer
control will require integration of this growing capacity
into cancer centers in LMICs. Partnerships between insti-
tutions within a country could ensure optimal use of re-
sources by leveraging capacity from one disease setting
(e.g. HIV) to another. Leveraging resources from in-
fectious disease infrastructure is particularly important
in light of the fact that a large percentage of cancers
in developing countries are infection-associated. For
example, allied health worker training could be en-
hanced by partnerships between neighboring institutes
or countries to help address the challenge of critical
shortages of health workforce and access to specialized
training that is required for optimal multidisciplinary
management of cancer patients.
Many partnerships between LMICs already exist in the
general areas of biotechnology and health, such as part-
nerships between Cuba and Brazil, South Africa and
India and Brazil, and partnerships between countries in
Africa. In large part, these partnerships tend to have a
commercial focus including development of novel anti-
cancer agents [14]. Some trilateral collaborations that in-
clude so-called “South-South” partnerships focus on
developing scientific and educational environments in
LMICs such as funding of innovative research through
the International Center for Genetic Engineering and
Biotechnology. In addition, South-South collaborations
have seen much success in the development of vaccines.
Given the development of HBV and HPV vaccines to
prevent cancer and the relative proportion of infectionattributable cancers in the LMICs, it is not difficult to
imagine how beneficial the integration of South-South
collaborative partnerships into cancer centers in LMICs
can be in strengthening cancer control and prevention.
To ensure the highest likelihood of success for new
and continued cancer center success in LMICs, a de-
tailed understanding of how challenges were addressed
previously is essential. Data on resources, capacities, pri-
orities, barriers, and the unique circumstances of local
institutes in LMICs that prevent, diagnose, treat, man-
age, and research cancers is needed for those seeking to
adapt successful models. Analysis of that data should an-
swer a number of key questions including: What are the
critical factors for success? What common (and less ob-
vious) pitfalls can be avoided? How do you ensure equity
and mutual benefit within partnerships? How do you
build trust within partnerships? How can evidenced-
based solutions be best adapted to the local context?
What standard operating procedures are prudent to have
in place?
The Cancer Centers in Low- and Middle-Income Countries
series is intended to make information and lessons-
learned about successful cancer centers in LMICs more
broadly available for those seeking to replicate successful
models and to help re-invigorate efforts to build effective
and sustainable partnerships. The series will provide a
platform to showcase detailed features of institutes from
LMICs and their collaborations including: (1) cancer cen-
ter activities and resources for prevention, diagnosis, treat-
ment and palliative care (available facilities, health care
worker resources, outreach programs, collaborations, re-
search projects, oncology-related training facilities, etc.);
(2) funding support from local government, foundations,
or privately borne by patients; (3) key features of the can-
cer center and its partnerships that contribute to its suc-
cess; (4) challenges, both universal and setting-specific,
and how they are addressed; (5) policy and practice impli-
cations including discussion of what could be adapted by
others, what gaps need to be addressed, and what differ-
ences might arise in other settings. With detailed informa-
tion in hand about the lessons learned in developing
successful cancer center programs in LMICs, those who
aim to address the growing burden of cancer in the devel-
oping world will be much better equipped to do so.
The authors’ opinions and conclusions cannot be con-
strued as official policy statements of NIH, HHS, or the
United States government.
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